Treatment of gerd
A surgical method involving stomach dissection and a movement restriction composition addresses the issue of cardia sliding by creating a pouch with dorsal gravity, effectively preventing reflux and hernias, and enabling monitoring.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IMPLANTICA PATENT LTD
- Filing Date
- 2025-06-26
- Publication Date
- 2026-06-25
AI Technical Summary
Existing treatments for Gastroesophageal Reflux Disease (GERD) are inadequate in preventing the cardia from sliding through the diaphragm opening, leading to recurrent reflux and hiatal hernias, and there is a need for a more effective surgical method to address this issue.
A surgical procedure involving the dissection of the stomach fundus and affixing it to the lower esophagus, with a movement restriction composition, such as silicone or polyurethane, positioned to create a pouch and invaginated within, with its center of gravity dorsal to the coronal plane, to prevent cardia sliding.
Effectively prevents the cardia from sliding into the thorax, reducing reflux and hiatal hernias, and allows for post-operative monitoring with a contrast agent like barium sulfate for position verification.
Smart Images
Figure EP2025068176_25062026_PF_FP_ABST
Abstract
Description
The provided document is a patent application for a medical device and method for treating Gastroesophageal Reflux Disease (GERD). The document details a surgical procedure and an implantable movement restriction composition. The invention describes a movement restriction composition, primarily made of silicone or polyurethane, for use in a surgical method to treat reflux disease. The surgery involves dissecting a part of the patient's stomach, specifically the fundus, and affixing it to the lower esophagus to create a pouch. The movement restriction composition is then placed and invaginated within this pouch. A key feature is the positioning of the center of gravity of this composition dorsal to the patient's coronal plane. This specific placement is designed to prevent the cardia (the upper part of the stomach) from sliding through the diaphragm opening into the thorax, which is a common issue in hiatal hernias and a cause of GERD.The composition can also include a contrast agent, such as barium sulfate (BaSO4), to make it visible on X-rays. This helps in post-operative monitoring of the implant's position. The patent also describes variations where the positioning is based on the center of gravity of the implant's boundary or on the majority of the implant's weight or volume being positioned dorsally.The document also contains numerous figures illustrating the anatomy, the device, and the surgical procedure. The description section is extensive, covering various embodiments and surgical techniques, including detailed steps for dissection, suturing, and implant placement. These are organized into numerous "aspect groups" which detail specific features and methods.
Claims
1. A movement restriction composition for use in a method of treatment of reflux disease treatment by surgery, the movement restriction composition comprising 50% - 100% silicone or 50% - 100% polyurethane, wherein a coronal plane of the patient divides the esophagus of the patient in an anterior half and a posterior half, and wherein the treatment by surgery comprises:dissecting an area of the patient's stomach,affixing the stomach fundus wall to the lower part of the patient's esophagus by providing sutures or staples,creating a pouch in the stomach fundus wall, andplacing and in-vaginating the movement restriction composition in the pouch by providing sutures or staples to the stomach fundus wall, characterized in that the center of gravity of the movement restriction composition is positioned dorsal to the coronal plane for preventing the cardia from sliding through the patient's diaphragm opening into the patient's thorax.
2. The movement restriction composition according to claim 1, wherein the movement restriction composition further comprises a contrast agent.
3. The movement restriction composition according to claim 2, wherein the contrast agent is BaSO4.
4. The movement restriction composition according to claim 2 or 3, wherein the movement restriction composition comprises the contrast agent in an amount of 1-15 % by weight of the movement restriction composition.
5. The movement restriction composition according to claim 4, wherein the movement restriction composition comprises the contrast agent in an amount of 1-6% by weight of the movement restriction composition.
6. A movement restriction composition for use in a method of treatment of reflux disease treatment by surgery, the movement restriction composition comprising 50% - 100% silicone or 50% - 100% polyurethane, wherein a coronal plane of the patient divides the esophagus of the patient in an anterior half and a posterior half, and wherein the treatment by surgery comprises:dissecting an area of the patient's stomach,affixing the stomach fundus wall to the lower part of the patient's esophagus by providing sutures or staples,creating a pouch in the stomach fundus wall, andplacing and in-vaginating the movement restriction composition in the pouch by providing sutures or staples to the stomach fundus wall, characterized in that the center of gravity of the boundary of the movement restriction composition is positioned dorsal to the coronal plane for preventing the cardia from sliding through the patient's diaphragm opening into the patient's thorax.
7. The movement restriction composition according to claim 6, wherein the movement restriction composition further comprises a contrast agent.
8. The movement restriction composition according to claim 7, wherein the contrast agent is BaSO4.
9. The movement restriction composition according to claim 6 or 7, wherein the movement restriction composition comprises the contrast agent in an amount of 1-15% by weight of the movement restriction composition.
10. The movement restriction composition according to claim 9, wherein the implantable movement restriction device comprises the contrast agent in an amount of 1-6% by weight of the movement restriction composition.
11. A movement restriction composition for use in a method of treatment of reflux disease treatment by surgery, the movement restriction composition comprising 50% - 100% silicone or 50% - 100% polyurethane, wherein a coronal plane of the patient divides the esophagus of the patient in an anterior half and a posterior half, and wherein the treatment by surgery comprises:dissecting an area of the patient's stomach,affixing the stomach fundus wall to the lower part of the patient's esophagus by providing sutures or staples,creating a pouch in the stomach fundus wall, andplacing and in-vaginating the movement restriction composition in the pouch by providing sutures or staples to the stomach fundus wall, characterized in that a majority by weight of the movement restriction composition is positioned dorsal to the coronal plane for preventing the cardia from sliding through the patient's diaphragm opening into the patient's thorax.
12. The movement restriction composition according to claim 11, wherein the movement restriction composition further comprises a contrast agent.
13. The movement restriction composition according to claim 12, wherein the contrast agent is BaSO4.
14. The movement restriction composition according to claim 11 or 12, wherein the movement restriction composition comprises the contrast agent in an amount of 1-15% by weight of the movement restriction composition.
15. The movement restriction composition according to claim 14, wherein the implantable movement restriction device comprises the contrast agent in an amount of 1-6% by weight of the movement restriction composition.
16. A movement restriction composition for use in a method of treatment of reflux disease treatment by surgery, the movement restriction composition comprising 50% - 100% silicone or 50% - 100% polyurethane, wherein a coronal plane of the patient divides the esophagus of the patient in an anterior half and a posterior half, and wherein the treatment by surgery comprises:dissecting an area of the patient's stomach,affixing the stomach fundus wall to the lower part of the patient's esophagus by providing sutures or staples,creating a pouch in the stomach fundus wall, andplacing and in-vaginating the movement restriction composition in the pouch by providing sutures or staples to the stomach fundus wall, characterized in that a majority by volume of the movement restriction composition is positioned dorsal to the coronal plane for preventing the cardia from sliding through the patient's diaphragm opening into the patient's thorax.
17. The movement restriction composition according to claim 16, wherein the composition further comprises a contrast agent.
18. The movement restriction composition according to claim 17, wherein the contrast agent is BaSO4.
19. The movement restriction composition according to claim 16 or 17, wherein the movement restriction composition comprises the contrast agent in an amount of 1-15% by weight of the movement restriction composition.
20. The movement restriction composition according to claim 19, wherein the implantable movement restriction device comprises the contrast agent in an amount of 1-6% by weight of the movement restriction composition.